• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Discontinuing Versus Switching BTK Inhibitors for Toxicity

Opinion
Video

Panelists discuss how data from Mansour and colleagues suggesting potential Bruton tyrosine kinase (BTK) inhibitor discontinuation after 2+ years of therapy opens up new treatment strategy considerations, with decisions between discontinuation vs switching to alternative BTK inhibitor (BTKi) therapy being influenced by factors such as depth and duration of response, toxicity severity, patient preferences regarding adverse effects and treatment schedules, and quality-of-life considerations.

Video content above is prompted by the following:

  • The ASH abstract by Mansour and colleagues suggests that for patients who have been on BTK inhibitors for more than 2 years, discontinuing therapy and observing the patient off-treatment might be an option, rather than switching to another BTKi immediately. What is your interpretation of this approach, and what factors would influence your decision to discontinue BTKi therapy due to toxicity instead of switching to an alternative BTKi?
  • How should patient preferences regarding adverse effects, treatment schedules, and efficacy trade-offs influence the decision to switch or continue BTKi therapy?
  • Consider reviewing the abstract by Ailawadhi and colleagues on patient preferences for BTKi.

Related Videos
2 experts in this video
2 experts in this video
Gladys Antelo-Allen
5 experts are featured in this series
1 expert is featured in this series.
Mikkael Sekeres, MD
Related Content
Female psychiatrist and male patient | Image Credit: N Lawrenson/peopleimages.com - stock.adobe.com

Decline in Psychiatrists Billing Medicare Part B Sparks Mental Health Access Concerns

February 10th 2025
Article

The number of psychiatrists submitting more than 10 claims to Medicare Part B decreased by 16.8% from 2014 to 2022.

Read More

managed care cast logo

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

December 23rd 2024
Podcast

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Listen

Non-Hodgkin Lymphoma wordcloud | Image Credit: © kalpis-stock.adobe.com.jpeg

Refining Remission Assessment in Aggressive B-Cell Lymphomas

February 7th 2025
Article

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, hurdles that include availability and cost remain to its widespread implementation.

Read More

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

December 17th 2024
Podcast

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Listen

Clinician taking blood pressure measurement | Image Credit: grinny - stock.adobe.com

Higher Dietary Inflammatory Index Scores Linked to Increased Youth Hypertension Risk

February 7th 2025
Article

A higher Dietary Inflammatory Index score was linked to an increased risk of hypertension in children and adolescents, emphasizing the role of diet in blood pressure regulation.

Read More

Myasthenia gravis | Image Credit: © Yurii Kibalnik-stock.adobe.com

Phase 3 Data Support Nipocalimab for Myasthenia Gravis

February 7th 2025
Article

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and efficacy of nipocalimab for myasthenia gravis.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.